The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity?
about
The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity?
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
The use of the tyrosine kinase ...... ent lead to vascular toxicity?
@en
The use of the tyrosine kinase ...... ent lead to vascular toxicity?
@nl
type
label
The use of the tyrosine kinase ...... ent lead to vascular toxicity?
@en
The use of the tyrosine kinase ...... ent lead to vascular toxicity?
@nl
prefLabel
The use of the tyrosine kinase ...... ent lead to vascular toxicity?
@en
The use of the tyrosine kinase ...... ent lead to vascular toxicity?
@nl
P2860
P1476
The use of the tyrosine kinase ...... ent lead to vascular toxicity?
@en
P2093
Guillaume Mahe
Vincent Jaquinandi
P2860
P2888
P356
10.1186/S12967-017-1334-1
P50
P577
2017-12-15T00:00:00Z
P6179
1099685448